These surgeries frequently involve patients with obesity and metabolic disease, who are most likely to be prescribed GLP-1 medications. At the studys conclusion, researchers found that use of GLP-1 and semaglutide was correlated with significantly lower chances for postoperative emergency department visits, without an increased surgical risk
How much is too much
Some people notice improved digestive regularity during this phase
Store in a dry place, in a closed container, at 1525C, out of reach of small children
2024 FDA Developments Several important FAA and FDA actions occurred in 2024: In January 2024, tirzepatide (Zepbound, Mounjanaro) was added to the FAAs Conditionally Acceptable Weight Loss Medications category, but medical certification required Special Issuance
Youll be working with Bonnie Lea Davis, FNP-C , a Board-Certified Nurse Practitioner specializing in GLP-1 and GIP weight loss treatments